Systemic inflammatory response syndrome in the course of status epilepticus: 7-year, two-center observational study

•A systemic inflammatory response frequently coexists with status epilepticus, and therefore should be assessed routinely.•The assessment of SIRS among SE patients, may contribute to more effective planning of treatment and outcome prediction.•There is a link between the presence of SIRS and resista...

Full description

Saved in:
Bibliographic Details
Published inEpilepsy research Vol. 137; pp. 53 - 55
Main Authors Szklener, Sebastian, Korchut, Agnieszka, Godek, Magdalena, Balicka-Adamik, Luiza, Bielecki, Dariusz, Rejdak, Robert, Rejdak, Konrad
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.11.2017
Subjects
Online AccessGet full text
ISSN0920-1211
1872-6844
1872-6844
DOI10.1016/j.eplepsyres.2017.09.003

Cover

Abstract •A systemic inflammatory response frequently coexists with status epilepticus, and therefore should be assessed routinely.•The assessment of SIRS among SE patients, may contribute to more effective planning of treatment and outcome prediction.•There is a link between the presence of SIRS and resistance to SE treatment. This study was aimed at identifying patients with systemic inflammatory response syndrome (SIRS) and determining whether the presence of SIRS on admission was associated with drug resistance and poor outcome in status epilepticus (SE) patients. We conducted a prospective review of patients consecutively admitted to two territory centers over a 7-year period. SIRS was considered present if the necessary criteria persisted for 12h. Other potential outcome predictors in a cohort of patients with SE were also collected. The primary outcome was defined as mortality during 30 days of observation, and the secondary outcome was defined as refractory SE. Logistic regression was used to determine independent predictors. Of 127 subjects, 85 patients met the inclusion criteria. In the entire population, 43% developed SIRS at SE onset and, among them, 16% had SIRS attributed to SE alone. Subjects with refractory SE accounted for 39%, and the mortality rate for the entire population was 35%. SIRS was independently associated with drug resistance (OR 3.93, 95% CI: 1.57–9.9) and death (OR 6.76, 95% CI: 1.33–34.32). We observed that approximately half of the patients with SE developed SIRS, and that SIRS is the independent risk factor for drug resistance and death. We also observed that SIRS was a secondary event for SE itself.
AbstractList This study was aimed at identifying patients with systemic inflammatory response syndrome (SIRS) and determining whether the presence of SIRS on admission was associated with drug resistance and poor outcome in status epilepticus (SE) patients. We conducted a prospective review of patients consecutively admitted to two territory centers over a 7-year period. SIRS was considered present if the necessary criteria persisted for 12h. Other potential outcome predictors in a cohort of patients with SE were also collected. The primary outcome was defined as mortality during 30 days of observation, and the secondary outcome was defined as refractory SE. Logistic regression was used to determine independent predictors. Of 127 subjects, 85 patients met the inclusion criteria. In the entire population, 43% developed SIRS at SE onset and, among them, 16% had SIRS attributed to SE alone. Subjects with refractory SE accounted for 39%, and the mortality rate for the entire population was 35%. SIRS was independently associated with drug resistance (OR 3.93, 95% CI: 1.57-9.9) and death (OR 6.76, 95% CI: 1.33-34.32). We observed that approximately half of the patients with SE developed SIRS, and that SIRS is the independent risk factor for drug resistance and death. We also observed that SIRS was a secondary event for SE itself.
•A systemic inflammatory response frequently coexists with status epilepticus, and therefore should be assessed routinely.•The assessment of SIRS among SE patients, may contribute to more effective planning of treatment and outcome prediction.•There is a link between the presence of SIRS and resistance to SE treatment. This study was aimed at identifying patients with systemic inflammatory response syndrome (SIRS) and determining whether the presence of SIRS on admission was associated with drug resistance and poor outcome in status epilepticus (SE) patients. We conducted a prospective review of patients consecutively admitted to two territory centers over a 7-year period. SIRS was considered present if the necessary criteria persisted for 12h. Other potential outcome predictors in a cohort of patients with SE were also collected. The primary outcome was defined as mortality during 30 days of observation, and the secondary outcome was defined as refractory SE. Logistic regression was used to determine independent predictors. Of 127 subjects, 85 patients met the inclusion criteria. In the entire population, 43% developed SIRS at SE onset and, among them, 16% had SIRS attributed to SE alone. Subjects with refractory SE accounted for 39%, and the mortality rate for the entire population was 35%. SIRS was independently associated with drug resistance (OR 3.93, 95% CI: 1.57–9.9) and death (OR 6.76, 95% CI: 1.33–34.32). We observed that approximately half of the patients with SE developed SIRS, and that SIRS is the independent risk factor for drug resistance and death. We also observed that SIRS was a secondary event for SE itself.
This study was aimed at identifying patients with systemic inflammatory response syndrome (SIRS) and determining whether the presence of SIRS on admission was associated with drug resistance and poor outcome in status epilepticus (SE) patients.OBJECTIVESThis study was aimed at identifying patients with systemic inflammatory response syndrome (SIRS) and determining whether the presence of SIRS on admission was associated with drug resistance and poor outcome in status epilepticus (SE) patients.We conducted a prospective review of patients consecutively admitted to two territory centers over a 7-year period. SIRS was considered present if the necessary criteria persisted for 12h. Other potential outcome predictors in a cohort of patients with SE were also collected. The primary outcome was defined as mortality during 30 days of observation, and the secondary outcome was defined as refractory SE. Logistic regression was used to determine independent predictors.METHODSWe conducted a prospective review of patients consecutively admitted to two territory centers over a 7-year period. SIRS was considered present if the necessary criteria persisted for 12h. Other potential outcome predictors in a cohort of patients with SE were also collected. The primary outcome was defined as mortality during 30 days of observation, and the secondary outcome was defined as refractory SE. Logistic regression was used to determine independent predictors.Of 127 subjects, 85 patients met the inclusion criteria. In the entire population, 43% developed SIRS at SE onset and, among them, 16% had SIRS attributed to SE alone. Subjects with refractory SE accounted for 39%, and the mortality rate for the entire population was 35%. SIRS was independently associated with drug resistance (OR 3.93, 95% CI: 1.57-9.9) and death (OR 6.76, 95% CI: 1.33-34.32).RESULTSOf 127 subjects, 85 patients met the inclusion criteria. In the entire population, 43% developed SIRS at SE onset and, among them, 16% had SIRS attributed to SE alone. Subjects with refractory SE accounted for 39%, and the mortality rate for the entire population was 35%. SIRS was independently associated with drug resistance (OR 3.93, 95% CI: 1.57-9.9) and death (OR 6.76, 95% CI: 1.33-34.32).We observed that approximately half of the patients with SE developed SIRS, and that SIRS is the independent risk factor for drug resistance and death. We also observed that SIRS was a secondary event for SE itself.CONCLUSIONSWe observed that approximately half of the patients with SE developed SIRS, and that SIRS is the independent risk factor for drug resistance and death. We also observed that SIRS was a secondary event for SE itself.
Author Bielecki, Dariusz
Rejdak, Konrad
Godek, Magdalena
Balicka-Adamik, Luiza
Szklener, Sebastian
Rejdak, Robert
Korchut, Agnieszka
Author_xml – sequence: 1
  givenname: Sebastian
  surname: Szklener
  fullname: Szklener, Sebastian
  organization: Department of Neurology, Medical University of Lublin, Poland
– sequence: 2
  givenname: Agnieszka
  surname: Korchut
  fullname: Korchut, Agnieszka
  organization: Department of Neurology, Medical University of Lublin, Poland
– sequence: 3
  givenname: Magdalena
  surname: Godek
  fullname: Godek, Magdalena
  organization: Department of Neurology, Medical University of Lublin, Poland
– sequence: 4
  givenname: Luiza
  surname: Balicka-Adamik
  fullname: Balicka-Adamik, Luiza
  organization: Department of Neurology, Public Hospital in Jarosław, Poland
– sequence: 5
  givenname: Dariusz
  surname: Bielecki
  fullname: Bielecki, Dariusz
  organization: Department of Neurology, Public Hospital in Jarosław, Poland
– sequence: 6
  givenname: Robert
  surname: Rejdak
  fullname: Rejdak, Robert
  organization: Department of General Ophthalmology, Medical University of Lublin, Poland
– sequence: 7
  givenname: Konrad
  surname: Rejdak
  fullname: Rejdak, Konrad
  email: konrad.rejdak@umlub.pl
  organization: Department of Neurology, Medical University of Lublin, Poland
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28938136$$D View this record in MEDLINE/PubMed
BookMark eNqNkUtv1TAQhS1URG8LfwF5yYKk40ceZoGACgpSJRbA2nKcifAliYPtFOXf48stIHV1N2NpfM6n0TkX5Gz2MxJCGZQMWH21L3EZcYlbwFhyYE0JqgQQj8iOtQ0v6lbKM7IDxaFgnLFzchHjHgAakPIJOeetEi0T9Y7EL1tMODlL3TyMZppM8mGjmbv4OSKN29wHP2H-puk7UuvXkNd-oDGZtEaKi8uXJGfX-Io2xYYmvKTply8szgkD9V3EcGeS87MZs2ntt6fk8WDGiM_u30vy7cP7r9cfi9vPN5-u394WVqomHSYfACqLXVtbpiojLBeqVxJQqK4V0kiA2iissBKqBsbagQ2qR9Oojlfikrw4cpfgf64Yk55ctDiOZka_Rs2U5I2oK8mz9Pm9dO0m7PUS3GTCpv8GlQXtUWCDjzHg8E_CQB860Xv9vxN96ESD0rmTbH39wGpd-hNICsaNpwDeHQGYw7pzGHS0DmeLvQtok-69OwXy5gHEjm521ow_cDsN8Rtoy8e6
CitedBy_id crossref_primary_10_1212_WNL_0000000000206838
crossref_primary_10_1097_WNP_0000000000000753
crossref_primary_10_1016_j_yebeh_2024_110232
crossref_primary_10_1186_s13578_022_00949_6
crossref_primary_10_2147_DDDT_S249162
crossref_primary_10_2174_1570159X21666221117152249
crossref_primary_10_1111_jcmm_14676
crossref_primary_10_1016_j_seizure_2020_08_021
crossref_primary_10_1111_epi_14524
crossref_primary_10_1111_epi_16842
crossref_primary_10_3389_fnmol_2018_00341
crossref_primary_10_1016_j_yebeh_2022_108649
crossref_primary_10_1016_j_seizure_2023_02_001
crossref_primary_10_1007_s12028_021_01256_7
crossref_primary_10_1248_bpb_b21_00574
crossref_primary_10_32587_jnic_2022_00514
crossref_primary_10_1038_s41598_024_72142_3
crossref_primary_10_3389_fneur_2022_964923
Cites_doi 10.1016/j.yebeh.2015.04.047
10.1016/j.yebeh.2016.09.036
10.1002/ana.24166
10.1186/s13054-015-1072-9
10.1111/epi.12271
10.1136/jnnp.2005.080887
10.1016/j.seizure.2017.01.004
10.1007/s12028-016-0255-9
ContentType Journal Article
Copyright 2017
Copyright © 2017. Published by Elsevier B.V.
Copyright_xml – notice: 2017
– notice: Copyright © 2017. Published by Elsevier B.V.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.eplepsyres.2017.09.003
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1872-6844
EndPage 55
ExternalDocumentID 28938136
10_1016_j_eplepsyres_2017_09_003
S0920121117301353
Genre Multicenter Study
Journal Article
Observational Study
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
1B1
1P~
1RT
1~.
1~5
29G
4.4
457
4G.
53G
5GY
5VS
7-5
71M
8P~
9JM
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATTM
AAXKI
AAXLA
AAXUO
AAYWO
ABBQC
ABCQJ
ABFNM
ABFRF
ABJNI
ABMAC
ABMZM
ABTEW
ABWVN
ABXDB
ACDAQ
ACGFO
ACGFS
ACIEU
ACIUM
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
AEBSH
AEFWE
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AGUBO
AGWIK
AGYEJ
AHHHB
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRLJ
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CS3
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HDW
HMK
HMO
HMQ
HVGLF
HZ~
IHE
J1W
K-O
KOM
L7B
LX8
M29
M2V
M41
MO0
MOBAO
N9A
O-L
O9-
OAUVE
OP~
OZT
P-8
P-9
P2P
PC.
Q38
R2-
ROL
RPZ
SAE
SCC
SDF
SDG
SEL
SES
SEW
SNS
SPCBC
SSH
SSN
SSZ
T5K
UNMZH
WUQ
Z5R
~G-
AACTN
AADPK
AAIAV
ABLVK
ABYKQ
AFCTW
AFKWA
AJBFU
AJOXV
AMFUW
EFLBG
LCYCR
RIG
AAYXX
AGRNS
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ACLOT
~HD
ID FETCH-LOGICAL-c497t-c492f005ceb86c195a3c239d940e39b834a4006a9e5e53960118f1f9dea79b253
IEDL.DBID .~1
ISSN 0920-1211
1872-6844
IngestDate Sun Sep 28 12:30:46 EDT 2025
Wed Feb 19 02:40:55 EST 2025
Tue Jul 01 03:29:45 EDT 2025
Thu Apr 24 22:51:37 EDT 2025
Fri Feb 23 02:30:55 EST 2024
Tue Aug 26 16:32:30 EDT 2025
IsPeerReviewed true
IsScholarly true
Language English
License Copyright © 2017. Published by Elsevier B.V.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c497t-c492f005ceb86c195a3c239d940e39b834a4006a9e5e53960118f1f9dea79b253
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
PMID 28938136
PQID 1942736542
PQPubID 23479
PageCount 3
ParticipantIDs proquest_miscellaneous_1942736542
pubmed_primary_28938136
crossref_primary_10_1016_j_eplepsyres_2017_09_003
crossref_citationtrail_10_1016_j_eplepsyres_2017_09_003
elsevier_sciencedirect_doi_10_1016_j_eplepsyres_2017_09_003
elsevier_clinicalkey_doi_10_1016_j_eplepsyres_2017_09_003
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate November 2017
2017-11-00
20171101
PublicationDateYYYYMMDD 2017-11-01
PublicationDate_xml – month: 11
  year: 2017
  text: November 2017
PublicationDecade 2010
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Epilepsy research
PublicationTitleAlternate Epilepsy Res
PublicationYear 2017
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References Gorter, van Vliet, Aronica (bib0020) 2015; 49
Janigro, Iffland, Marchi, Granata (bib0025) 2013; 54
Claassen, Albers, Schmidt, De Marchis, Pugin, Falo, Mayer, Cremers, Agarwal, Elkind, Connolly, Dukic, Hripcsak, Badjatia (bib0010) 2014; 75
Sutter, Valença, Tschudin-Sutter, Rüegg, Marsch (bib0040) 2015; 9
Pacha, Orellana, Silva, Ernst, Pantiu, Quiroga Narvaez, Reisin, Martinez (bib0030) 2016; 64
Boehme, Hays, Kicielinski, Arora, Kapoor, Lyerly, Gadpaille, Shiue, Albright, Miller, Elkind, Harrigan (bib0005) 2016; 25
Rossetti, Hurwitz, Logroscino, Bromfield (bib0035) 2006; 77
Giovannini, Monti, Tondelli, Marudi, Valzania, Leitinger, Trinka, Meletti (bib0015) 2017; 46
Rossetti (10.1016/j.eplepsyres.2017.09.003_bib0035) 2006; 77
Claassen (10.1016/j.eplepsyres.2017.09.003_bib0010) 2014; 75
Gorter (10.1016/j.eplepsyres.2017.09.003_bib0020) 2015; 49
Giovannini (10.1016/j.eplepsyres.2017.09.003_bib0015) 2017; 46
Sutter (10.1016/j.eplepsyres.2017.09.003_bib0040) 2015; 9
Boehme (10.1016/j.eplepsyres.2017.09.003_bib0005) 2016; 25
Pacha (10.1016/j.eplepsyres.2017.09.003_bib0030) 2016; 64
Janigro (10.1016/j.eplepsyres.2017.09.003_bib0025) 2013; 54
References_xml – volume: 49
  start-page: 13
  year: 2015
  end-page: 16
  ident: bib0020
  article-title: Status epilepticus, blood-brain barrier disruption, inflammation, and epileptogenesis
  publication-title: Epilepsy Behav.
– volume: 46
  start-page: 31
  year: 2017
  end-page: 37
  ident: bib0015
  article-title: Mortality, morbidity and refractoriness prediction in status epilepticus: comparison of STESS and EMSE scores
  publication-title: Seizure
– volume: 77
  start-page: 611
  year: 2006
  end-page: 615
  ident: bib0035
  article-title: Prognosis of status epilepticus: role of aetiology, age, and consciousness impairment at presentation
  publication-title: J. Neurol. Neurosurg. Psychiatry
– volume: 75
  start-page: 771
  year: 2014
  end-page: 781
  ident: bib0010
  article-title: Nonconvulsive seizures in subarachnoid hemorrhage link inflammation and outcome
  publication-title: Ann. Neurol.
– volume: 25
  start-page: 133
  year: 2016
  end-page: 140
  ident: bib0005
  article-title: Systemic inflammatory response syndrome and outcomes in intracerebral hemorrhage
  publication-title: Neurocrit. Care
– volume: 9
  start-page: 361
  year: 2015
  ident: bib0040
  article-title: Procalcitonin and mortality in status epilepticus: an observational cohort study
  publication-title: Crit. Care
– volume: 54
  start-page: 30
  year: 2013
  end-page: 32
  ident: bib0025
  article-title: A role for inflammation in status epilepticus is revealed by a review of current therapeutic approaches
  publication-title: Epilepsia
– volume: 64
  start-page: 140
  year: 2016
  end-page: 142
  ident: bib0030
  article-title: Role of EMSE and STESS scores in the outcome evaluation of status epilepticus
  publication-title: Epilepsy Behav.
– volume: 49
  start-page: 13
  year: 2015
  ident: 10.1016/j.eplepsyres.2017.09.003_bib0020
  article-title: Status epilepticus, blood-brain barrier disruption, inflammation, and epileptogenesis
  publication-title: Epilepsy Behav.
  doi: 10.1016/j.yebeh.2015.04.047
– volume: 64
  start-page: 140
  year: 2016
  ident: 10.1016/j.eplepsyres.2017.09.003_bib0030
  article-title: Role of EMSE and STESS scores in the outcome evaluation of status epilepticus
  publication-title: Epilepsy Behav.
  doi: 10.1016/j.yebeh.2016.09.036
– volume: 75
  start-page: 771
  year: 2014
  ident: 10.1016/j.eplepsyres.2017.09.003_bib0010
  article-title: Nonconvulsive seizures in subarachnoid hemorrhage link inflammation and outcome
  publication-title: Ann. Neurol.
  doi: 10.1002/ana.24166
– volume: 9
  start-page: 361
  issue: 19
  year: 2015
  ident: 10.1016/j.eplepsyres.2017.09.003_bib0040
  article-title: Procalcitonin and mortality in status epilepticus: an observational cohort study
  publication-title: Crit. Care
  doi: 10.1186/s13054-015-1072-9
– volume: 54
  start-page: 30
  year: 2013
  ident: 10.1016/j.eplepsyres.2017.09.003_bib0025
  article-title: A role for inflammation in status epilepticus is revealed by a review of current therapeutic approaches
  publication-title: Epilepsia
  doi: 10.1111/epi.12271
– volume: 77
  start-page: 611
  year: 2006
  ident: 10.1016/j.eplepsyres.2017.09.003_bib0035
  article-title: Prognosis of status epilepticus: role of aetiology, age, and consciousness impairment at presentation
  publication-title: J. Neurol. Neurosurg. Psychiatry
  doi: 10.1136/jnnp.2005.080887
– volume: 46
  start-page: 31
  year: 2017
  ident: 10.1016/j.eplepsyres.2017.09.003_bib0015
  article-title: Mortality, morbidity and refractoriness prediction in status epilepticus: comparison of STESS and EMSE scores
  publication-title: Seizure
  doi: 10.1016/j.seizure.2017.01.004
– volume: 25
  start-page: 133
  year: 2016
  ident: 10.1016/j.eplepsyres.2017.09.003_bib0005
  article-title: Systemic inflammatory response syndrome and outcomes in intracerebral hemorrhage
  publication-title: Neurocrit. Care
  doi: 10.1007/s12028-016-0255-9
SSID ssj0007044
Score 2.3006055
Snippet •A systemic inflammatory response frequently coexists with status epilepticus, and therefore should be assessed routinely.•The assessment of SIRS among SE...
This study was aimed at identifying patients with systemic inflammatory response syndrome (SIRS) and determining whether the presence of SIRS on admission was...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 53
SubjectTerms Aged
Drug Resistance
Female
Follow-Up Studies
Humans
Logistic Models
Male
Middle Aged
Prospective Studies
Status Epilepticus - complications
Status Epilepticus - drug therapy
Status Epilepticus - mortality
Status Epilepticus - physiopathology
Systemic Inflammatory Response Syndrome - complications
Systemic Inflammatory Response Syndrome - drug therapy
Systemic Inflammatory Response Syndrome - mortality
Systemic Inflammatory Response Syndrome - physiopathology
Title Systemic inflammatory response syndrome in the course of status epilepticus: 7-year, two-center observational study
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0920121117301353
https://dx.doi.org/10.1016/j.eplepsyres.2017.09.003
https://www.ncbi.nlm.nih.gov/pubmed/28938136
https://www.proquest.com/docview/1942736542
Volume 137
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier)
  customDbUrl:
  eissn: 1872-6844
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0007044
  issn: 0920-1211
  databaseCode: GBLVA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier ScienceDirect
  customDbUrl:
  eissn: 1872-6844
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0007044
  issn: 0920-1211
  databaseCode: ACRLP
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection Journals [SCFCJ] - NZ
  customDbUrl:
  eissn: 1872-6844
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0007044
  issn: 0920-1211
  databaseCode: AIKHN
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: ScienceDirect Freedom Collection 2013
  customDbUrl:
  eissn: 1872-6844
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0007044
  issn: 0920-1211
  databaseCode: .~1
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVLSH
  databaseName: Elsevier Journals
  customDbUrl:
  mediaType: online
  eissn: 1872-6844
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0007044
  issn: 0920-1211
  databaseCode: AKRWK
  dateStart: 19870101
  isFulltext: true
  providerName: Library Specific Holdings
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fa9swEBalg9GX0Xbrlq4rGow-xYtt2Za1PZWykm20FNZC34SknCGji02cMPKyv313kp0wSiGwF4N_HJal0-nO-u47xj4UIApZmQSVt4QoM7KKytzYKBGFMy62k8pXnru6LsZ32bf7_H6HXfS5MASr7Gx_sOneWndXRl1vjprpdPQjVqknKEtISUVOjJ_E_oU6_fHPBuYhY1_QlR6O6OkOzRMwXtA8QNOuMLAlkJf0jKd9-azHS9RTLqhfii732YvOh-TnoZkHbAdmh-z5VbdLfsjObgIf9WrIbzfpVe2Qn_GbDVP16iVrA1_51HHUM1SNX37Lnc8DbhZ4T2eAtzk6itzVBPngdcUpD2nZcmjQqDTE39F-4jJa4bQZ8sXvOiLMJ8x5bdc_fbHBnsr2Fbu7_HJ7MY66KgyRy5Rc0DGtcK46sGXhEpUb4VKhJiqLQShbisygHSiMghxygQERhixVUqkJGKlsmosjtjurZ_CGceVUatDlxBURbYUlV0VJ63LrDKROlgMm-47XrqMop0oZD7rHov3UmyHTNGQ6VkRvOmDJWrIJNB1byKh-bHWfhoqGU-NasoXs57XsP-q6pfT7XpU0zmbaojEzqJetTlSG_iQVERuw10HH1t-DoTG6V6I4_q93v2V7dBbSKU_Y7mK-hHfoVy3sqZ84p-zZ-dfv4-u_SJMmgQ
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fa9swED66FLa9jK7burT7ocHoU0xsy7Ks7qmUlXRtQmEp9E1IigwZXWzihJL_fidbdihjENiLHywflqXTpzvr7juAr6mlKc9VhMqb2SBRPA8ypnQQ0dQoE-pZXleeG0_S0V3y457d78FFmwvjwio99jeYXqO1vzP0ozks5_Phz1DENUFZ5JSUMvoM9hOGmNyD_fOr69GkA2Qe1jVd3fOBE_ABPU2Yly0fbFlt0Ld1cV68Jj1tK2j9vUv9ywqtd6PLA3jlzUhy3vT0NezZxSE8H_uD8kM4vW0oqTcDMt1mWFUDckput2TVmzdQNZTlc0NQ1VA7ften7mTZhM5a0jIaYDNBW5GYwkV9kCInLhVpXRFbIq6UjsKjOiM82ODKGZDVYxG4sE-7JIXu_vtih2s227dwd_l9ejEKfCGGwCSCr9w1znG5Gquz1ESCKWpiKmYiCS0VOqOJQihIlbDMMoo-EXoteZSLmVVc6JjRd9BbFAv7HogwIlZodeKmiHChnbUiuDZMG2Vjw7M-8HbgpfEs5a5YxoNsw9F-ye2USTdlMhSO4bQPUSdZNkwdO8iIdm5lm4mK2ClxO9lB9lsn-0Rjd5T-0qqSxAXtTmnUwhbrSkYiQZPS1RHrw1GjY933oHeMFhZNj__r3Z_hxWg6vpE3V5PrE3jpWprsyg_QWy3X9iOaWSv9yS-jPyvYKSw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Systemic+inflammatory+response+syndrome+in+the+course+of+status+epilepticus%3A+7-year%2C+two-center+observational+study&rft.jtitle=Epilepsy+research&rft.au=Szklener%2C+Sebastian&rft.au=Korchut%2C+Agnieszka&rft.au=Godek%2C+Magdalena&rft.au=Balicka-Adamik%2C+Luiza&rft.date=2017-11-01&rft.pub=Elsevier+B.V&rft.issn=0920-1211&rft.volume=137&rft.spage=53&rft.epage=55&rft_id=info:doi/10.1016%2Fj.eplepsyres.2017.09.003&rft.externalDocID=S0920121117301353
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0920-1211&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0920-1211&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0920-1211&client=summon